Topical mTOR inhibitors for cutaneous proliferative and vascular conditions
Inventors
DEKLOTZ, Cynthia Marie Carver • Silverman, Robert A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Methods for the treatment of cutaneous vascular conditions and cutaneous proliferative conditions are provided. The methods employ topical administration of mammalian target of rapamycin (mTOR) inhibitors such as sirolimus (rapamycin) and everolimus. Conditions treatable by the disclosed methods include venolymphatic malformations, acne, acne rosacea, periorificial dermatitis, acne vulgaris, cutaneous capillary malformation-arteriovenous malformation (CM-AVM) syndrome, RASopathies, Langerhans cell histiocytosis, non-Langerhans cell histiocytosis, scars, hypertrophic or keloidal scars, Proteus syndrome, PIK3CA-related overgrowth spectrum (PROS), PTEN hamartoma tumor syndromes, cutaneous malignancies and tumors associated with PI3K/AKT/mTOR mutations, keratodermas, acanthosis nigricans, Birt-Hogg-Dube syndrome, Brooke-Speigler syndrome, cylindromas, and epidermal nevi. Also provided are formulations and pharmaceutical compositions having mTOR inhibitor as principal therapeutically active ingredient useful in practicing the methods.
Core Innovation
The invention relates to treating cutaneous proliferative conditions by topically administering a therapeutically effective amount of a mammalian target of rapamycin (mTOR) inhibitor to an affected area of a subject in need thereof. The cutaneous proliferative condition is a cutaneous histiocytosis, including Langerhans cell histiocytosis or non-Langerhans cell histiocytosis (non-LCH). The topical mTOR inhibitor is selected from sirolimus and everolimus.
The topical mTOR inhibitor is provided as a topical formulation comprising 0.01% to 10% (w/w) of the mTOR inhibitor in a pharmaceutically acceptable carrier. The approach is directed to topical administration to the affected area, thereby treating the specified cutaneous histiocytosis. Additional refinements specify the affected area including at least part of the head, face, and neck, and include subject age groups such as a human under 18 years of age.
Claims Coverage
The provided claims include one independent claim directed to a topical treatment method for a cutaneous histiocytosis using an mTOR inhibitor formulation. Dependent claims provide inventive-feature refinements including histiocytosis subtype selection, restriction of the affected area, patient age limitations, and specific concentration examples.
Topical mTOR inhibitor treatment of cutaneous histiocytosis
Topically administering to an affected area a therapeutically effective amount of a mammalian target of rapamycin (mTOR) inhibitor, thereby treating a cutaneous proliferative condition that is a cutaneous histiocytosis.
Sirolimus or everolimus as the topical mTOR inhibitor
Selecting the mTOR inhibitor from the group consisting of sirolimus and everolimus for topical administration to the affected area.
Topical formulation with 0.01% to 10% (w/w) in pharmaceutically acceptable carrier
Providing the mTOR inhibitor as a topical formulation comprising 0.01% to 10% (w/w) of the mTOR inhibitor in a pharmaceutically acceptable carrier.
Langerhans versus non-Langerhans cell histiocytosis selection
Wherein the cutaneous histiocytosis is selected from Langerhans cell histiocytosis or non-Langerhans cell histiocytosis (non-LCH).
Named histiocytosis disorder selection
Selecting the histiocytosis from a specified group of named histiocytosis disorders.
Affected area includes head/face/neck
Wherein the affected area includes at least part of any one or more of the head, face, and neck.
Pediatric subject under 18 years of age
Applying the method when the subject is a human under 18 years of age.
Example formulation with 1% concentration
Specifying that the topical formulation includes 1% of an mTOR inhibitor in a pharmaceutically acceptable carrier.
Overall, the claim set covers topical treatment of cutaneous histiocytosis using sirolimus or everolimus formulated at 0.01% to 10% (w/w) in a pharmaceutically acceptable carrier, with dependent refinements for histiocytosis subtype selection (LCH vs non-LCH and further named disorders), affected-area location (head/face/neck), patient age (under 18), and a specific example concentration (1%).
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?